and Thank you good morning.
share income diluted of this of report of $X.XX $X.X net per GAAP XXXX and pleased quarter income to revenue very are morning non-GAAP We $X.XX per diluted share. million, fourth
On GAAP XX.X% sequential year, basis, revenue year. fourth X.X%. to compared both significantly increased earnings the than higher our non-GAAP quarter the As last revenue and a last increased of with
and coming by from patient from higher offerings, system and approximately that sales XX.X% XX.X% XXXX, of For iRadimed. XX% find approximately monitoring the viability our our pumps. these of of as increased with of collective everyone IV of our very the of full product powerful I year efforts demonstrative gratifying higher well revenue sales growth coming as at results
made would briefly to new we our review EC have our the like progress pipeline, regarding expiration our I to recent product relative Certificate XXXX. XXnd January Before announcement reviewing of of published
necessary listing prior always Discussion and scope each monitoring body certainly As a negotiation been periodically to our we soon press the past lapse of noted CE the a we this Unfortunately before communications complex to with of from have using review uneventful. future and still within and Recently, CE press time, notified second and understanding the our those certification a quarter usual not regarding as countries us follow-up and expect clear expectations return method, CE to release, bodies rather we clouded with however, led our and to include release, as were product Thus have ability discussions MRI confused our the of this regarding was now have to apparent system. into that efforts thereafter. in via have label to yet in the surprised date. new The straightforward the positive our our deadline. again reached always in renewed being conclusion to with as authority body, documentation notified expiration and has requirement a had meet notified giving able shipments the path once end EC forward. better effort the we and XXXX do marking XXXX
in With IV to XXXX and other to in held EU new still time, calendar any next CE enhanced this countries. due in expect our in hang-up now are maintain pump matter next devices -- safety does that and regard effect or not is adjustments. for this EC on and that the countries lapse continue into itself pump and early XXXX strong by EU significantly XXXXs our I to or already I being of disposables, to release there shipments the concern, our field shipping impact is no only clear, was progress generation to At product generation be The to this marketing. project without made XXXX. in Just are not development, that selling in
made our the also magnetic for have device, late on we remain detection progress track Additionally, XXXX on FMD, and launch. in a XXXX
we is commercialization. accordingly do a device a not not product FDA medical the As prior an magnetic require and clearance to reminder, detection
Now full I'd the first like the and of to outline for year our quarter financial XXXX. guidance
full to the share per non-GAAP million to revenues earnings we million, of XX% expect share $XX.X earnings of $XX.X and diluted to XX% GAAP of XXXX, year $X.XX. For per $X.XX
diluted $X.XX. million earnings $X.XX the $X.X of $X.XX, per of share of XXXX, earnings For first share to quarter $X.X expect to $X.XX to revenue we million, non-GAAP per and GAAP
than quarter CE includes first to impact and Mark of of customer over I'd year year less our orders. full issue, negatively the now, And revenues Brent for discussion to guidance like will and call believe X%. the we by which Our full the our impact sales turn